In a first-in-human study, researchers at The University of Texas MD Anderson Cancer Center observed strong responses and early signs of antitumor activity in patients with difficult-to-treat ...
In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol and triglycerides in people with difficult-to-treat lipid disorders, ...
Kelonia Therapeutics Presents First-in-Human Data From Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting 100% MRD-negative ...
SHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging ...
Automation has reshaped work over the past few decades, bringing notable improvements in speed, scale, and efficiency across industries. Consequently, machines and software took over repetitive tasks, ...
In a bid to treat blindness, Life Biosciences will try out potent cellular reprogramming technology on volunteers. When Elon Musk was at Davos last week, an interviewer asked him if he thought aging ...